ReviewUrologic oncology2016
Prostate cancer risk stratification with magnetic resonance imaging.
Review in Urologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- PRECISE Assessment of Sequential Biparametric MRI and Clinically Significant Prostate Cancer in Biopsy-naive Men: A Retrospective Cohort Study.European urology open science · 2026Article
- Trends in the Adoption of MRI Associated Biopsy for Active Surveillance Within the First Year After Localized Prostate Cancer Diagnosis: A SEER-Medicare Cohort Study.Cancer medicine · 2026Article
- Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.Cancers · 2026Review
- Beyond PSMA: The essential complementary role of MRI in staging prostate cancer with Low-PSMA expression phenotypes.European journal of nuclear medicine and molecular imaging · 2026Article
- Automated machine learning for prostate cancer detection and Gleason score prediction using T2WI: a diagnostic multi-center study.BMC cancer · 2025Article
- Evaluating the feasibility of AI-predicted bpMRI image features for predicting prostate cancer aggressiveness: a multi-center study.Insights into imaging · 2025Article
- MRI grading for the prediction of prostate cancer aggressiveness.European radiology · 2022Article
- Diffusion-Weighted MRI in the Genitourinary System.Journal of clinical medicine · 2022Review
- Semi-automated PIRADS scoring via mpMRI analysis.Journal of medical imaging (Bellingham, Wash.) · 2020Article
- Role of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Assessment.Acta clinica Croatica · 2018Review
- Anatomic and Molecular Imaging in Prostate Cancer.Cold Spring Harbor perspectives in medicine · 2018Review
- MR-guided biopsy and focal therapy: new options for prostate cancer management.Current opinion in urology · 2018Review
- Multiparametric magnetic resonance imaging of the prostate with computer-aided detection: experienced observer performance study.European radiology · 2017Article
- The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.Current urology reports · 2017Review
- Role of prostate magnetic resonance imaging in active surveillance.Translational andrology and urology · 2017Review
- Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy.The Journal of urology · 2017Article
- Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI.Journal of magnetic resonance imaging : JMRI · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In recent years, multiparametric magnetic resonance imaging (mpMRI) has shown promise for prostate cancer (PCa) risk stratification. mpMRI, often followed by targeted biopsy, can be used to confirm low-grade disease before enrollment in active surveillance. In patients with intermediate or high-risk PCa, mpMRI can be used to inform surgical management. mpMRI has sensitivity of 44% to 87% for detection of clinically significant PCa and negative predictive value of 63% to 98% for exclusion of significant disease. In addition to tumor identification, mpMRI has also been shown to contribute significant incremental value to currently used clinical nomograms for predicting extraprostatic extension. In combination with conventional clinical criteria, accuracy of mpMRI for prediction of extraprostatic extension ranges from 92% to 94%, significantly higher than that achieved with clinical criteria alone. Supplemental sequences, such as diffusion-weighted imaging and dynamic contrast-enhanced imaging, allow quantitative evaluation of cancer-suspicious regions. Apparent diffusion coefficient appears to be an independent predictor of PCa aggressiveness. Addition of apparent diffusion coefficient to Epstein criteria may improve sensitivity for detection of significant PCa by as much as 16%. Limitations of mpMRI include variability in reporting, underestimation of PCa volume and failure to detect clinically significant disease in a small but significant number of cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.